Inozyme Pharma

$27.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.85 (+3.23%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Inozyme Pharma and other stocks, options, and ETFs commission-free!

About INZY

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA. The listed name for INZY is Inozyme Pharma, Inc. Common Stock.

CEO

Axel Bolte

Employees

—

Headquarters

Boston, Massachusetts

Founded

2015

Market Cap

635.04M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

36.36K

High Today

$28.40

Low Today

$26.06

Open Price

$26.18

Volume

45.05K

52 Week High

$31.65

52 Week Low

$16.10

Collections

New On Robinhood

INZY Earnings

-$7.57

-$5.05

-$2.52

$0.00

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 25, Pre-Market